免疫介导性巨线粒体肌病:一种新型自身免疫性肌病亚型
该病例系列回顾梅奥诊所肌肉病理数据库(2018–2023年),识别出5例具有巨线粒体病理、亚急性进行性无力和高肌酸激酶血症、临床类似肌炎的患者。所有患者近端无力、肌酸激酶升高(1,214–5,920 U/L)、肌炎抗体阴性、坏死性肌病理,非坏死肌纤维含巨线粒体;4例免疫组化显示肌膜MHC-1和C5b9免疫反应性;4/5例CHKB测序无异常;4例接受免疫调节治疗者无力和高肌酸激酶血症改善。作者认为除不可治愈的CHKB-先天性肌营养不良外,巨线粒体也可见于这一可治疗的新型自身免疫性肌病亚型IMMM。
要点
- 免疫介导性巨线粒体肌病(IMMM)表现为亚急性进行性近端无力、肌酸激酶升高和坏死性肌病理。
- 所有患者肌炎抗体阴性,非坏死肌纤维含巨线粒体,4例免疫组化显示肌膜MHC-1和C5b9免疫反应性。
- 4例接受免疫调节治疗者无力和高肌酸激酶血症改善。
核心结论
- 除不可治愈的CHKB-先天性肌营养不良外,巨线粒体也可见于这一可治疗的新型自身免疫性肌病亚型IMMM。
- IMMM与胰腺疾病之间的关联尚待阐明。
研究设计与样本
- 病例系列研究,回顾梅奥诊所肌肉病理数据库2018–2023年,识别具有巨线粒体病理、亚急性进行性无力和高肌酸激酶血症、临床类似肌炎的患者。
- 共识别5例患者,另从其他机构招募1例具有相似临床病理特征的患者。
主要发现
- 5例患者无力起病年龄范围为19至45.5岁。
- 所有患者均有近端无力、肌酸激酶水平升高(1,214至5,920 U/L)、肌炎抗体阴性、坏死性肌病理,非坏死肌纤维含巨线粒体。
- 4例患者免疫组化显示肌膜MHC-1和C5b9免疫反应性。
- 4/5例患者CHKB测序无异常发现。
- 4例接受免疫调节治疗的患者无力和高肌酸激酶血症改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe a novel subtype of autoimmune myopathy, immune-mediated megaconial myopathy (IMMM), myopathologically characterized by giant mitochondria (megaconia). METHODS: In this case series, we reviewed the Mayo Clinic Muscle Pathology database, between 2018 and 2023, to identify patients with megaconial pathology, subacute progressive weakness, and hyperCKemia, clinically resembling myositis. We recruited 1 patient from another institute, who had similar clinicopathologic features. RESULTS: Five patients were identified. Age at onset of weakness ranged from 19 to 45.5 years. All patients had proximal weakness, elevated creatine kinase levels (1,214 to 5,920 U/L), negative myositis antibodies, necrotizing myopathology, and nonnecrotic myofibers harboring giant mitochondria. Immunohistochemical studies conducted in 4 patients showed sarcolemmal MHC-1 and C5b9 immunoreactivities. Megaconial pathology was considered pathognomonic of congenital muscular dystrophy due to biallelic pathogenic variants in CHKB. Sequencing of CHKB in 4/5 patients was unrevealing. Immunomodulatory therapy improved weakness and hyperCKemia in 4 treated patients. Of interest, all patients had coexisting pancreatic diseases (3 cystic fibrosis-related exocrine pancreatic insufficiency, 1 pancreatic cancer, and 1 pancreatitis). DISCUSSION: In addition to incurable CHKB-congenital muscular dystrophy, giant mitochondria can also occur in this new subtype of treatable autoimmune myopathy, IMMM. The association between IMMM and pancreatic disorders remains to be elucidated.
引用
- Santilli AR, Ni O, Milone M, et al. Immune-Mediated Megaconial Myopathy: A Novel Subtype of Autoimmune Myopathy. Neurology. 2024. PMID: 39475687. doi:10.1212/WNL.0000000000210001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。